Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects

NCT04588129 is registered in ClinicalTrials.gov with LB Pharmaceuticals Inc. as lead sponsor.

NCT NCT04588129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects
Lead sponsor
LB Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 5, 2021
Completion date
November 15, 2021
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia